Clindamycin Hydrochloride Capsules — Class II drug recall D-0391-2025
Ongoing recall by Preferred Pharmaceuticals, Inc., reported 2025-05-07, distributed nationwide. cGMP Deviations
| Recall number | D-0391-2025 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Preferred Pharmaceuticals, Inc., Anaheim, CA, United States |
| Recall initiated | 2025-04-18 |
| Classified | 2025-04-28 |
| Reported by FDA | 2025-05-07 |
| Distributed | Nationwide (US) |
| Quantity | 1,190 bottles |
| Reason classes | cgmp |
| NDC | 68788-8685-03 |
| Lot numbers | A0925F, I1024O, I2424E, J0824O, J1624V, K0124N, K1824M, L0224T, L2324L |
| Expiration dates | 2026-07-31 |
Product
Clindamycin Hydrochloride Capsules, USP, 300mg, 30-count bottles, Manufactured by: Glenmark Pharmaceuticals Limited, NDC 68788-8685-03.
Reason for recall
cGMP Deviations
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0391-2025. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.